Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.55) per share and revenue of $0.70 million for the quarter.
Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.15. On average, analysts expect Outlook Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Outlook Therapeutics Stock Performance
Shares of OTLK stock traded up $0.01 during midday trading on Monday, hitting $1.76. 621,543 shares of the company were exchanged, compared to its average volume of 750,204. The firm has a market capitalization of $57.41 million, a P/E ratio of -0.24 and a beta of 0.39. The firm's 50 day moving average price is $1.45 and its two-hundred day moving average price is $2.13. Outlook Therapeutics has a 52 week low of $0.87 and a 52 week high of $9.25.
Analysts Set New Price Targets
OTLK has been the subject of several research analyst reports. Chardan Capital reaffirmed a "neutral" rating and set a $3.00 target price on shares of Outlook Therapeutics in a report on Tuesday, February 18th. Ascendiant Capital Markets cut their price objective on shares of Outlook Therapeutics from $33.00 to $24.00 and set a "buy" rating for the company in a report on Monday, February 24th. Finally, HC Wainwright cut their price objective on shares of Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating for the company in a report on Tuesday, February 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.20.
Read Our Latest Stock Report on Outlook Therapeutics
Institutional Trading of Outlook Therapeutics
A hedge fund recently raised its stake in Outlook Therapeutics stock. AQR Capital Management LLC raised its holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 42.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 84,671 shares of the company's stock after purchasing an additional 25,351 shares during the period. AQR Capital Management LLC owned approximately 0.26% of Outlook Therapeutics worth $103,000 at the end of the most recent quarter. 11.20% of the stock is owned by institutional investors and hedge funds.
About Outlook Therapeutics
(
Get Free Report)
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
See Also
Before you consider Outlook Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.
While Outlook Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
